HC Wainwright & Co. Reiterates Buy on Novavax, Maintains $35 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a 'Buy' rating on Novavax (NASDAQ:NVAX) and maintained a $35 price target.
August 10, 2023 | 11:43 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novavax's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $35.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $35 indicates the firm's continued confidence in the company's potential. This could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100